Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

OTOdyssey Therapeutics, Inc.

$16.8

+0.19 (+1.14%)

D 31Pipeline Score Richly Valued Biotech · Clinical
Market Cap
828.35 M
EPS
-
P/E Ratio
-
Value Trade
6.11 M
2.04 %
Week
5.68 %
1 Month
5.68 %
3 Month
5.68 %
6 Month
5.68 %
5 Year
5.68 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
206.82 K
52 Week Range
16.41 - 18.43
% held by Insiders
40.7 %
% held by Institutions
9.53 %
Enterprise Value
1.38 B
Total Shares
47.33 M
Short %
4.72 %
Float Shares
18.69 M
Company Description
HQ: 51 SLEEPER STREET, BOSTON, MA,...
https://www.odysseytx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2a data readout example
OD-001 (RIPK2 scaffolding inhibitor) moderate to severe ulcerative colitis
Phase 2a
—

Subscribe to access the data.

Small Molecules
Digestive System
OD-001 (RIPK2 scaffolding inhibitor) moderate to severe ulcerative colitis
Phase 2a
—

Subscribe to access the data.

Small Molecules
Digestive System
OD-001 (RIPK2 scaffolding inhibitor) moderate to severe ulcerative colitis
Phase 2a
—

Subscribe to access the data.

Small Molecules
Digestive System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D31
Pipeline Score
$121M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 36%
Micro Cap
(rank 581 of 906)
Percentile Rank
Odyssey Therapeutics, Inc. faces pipeline headwinds (31/100), with $450M risk-adjusted pipeline value, led by OD-07656 in Inflammatory Bowel Diseases (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
OD-07656
Small molecule		Ulcerative Colitis (UC)Phase 2NCT0685072717% $408M RECRUITING 57 STALLED B (63) Nov 1, 2026 -
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
OD-001
ulcerative colitis
Phase 2a
2026-06-17

patients completed: 49; clinical remission: 27%; clinical response: 61%

Read More

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Read More
OD-001
ulcerative colitis
Phase 2a
2026-06-17

patients completed: 49; clinical remission: 27%; clinical response: 61%

Read More

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Read More
OD-001
ulcerative colitis
Phase 2a
2026-06-17

patients completed: 49; clinical remission: 27%; clinical response: 61%

Read More

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ODTX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
ODTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ODTX
Jun 17, 2026
ODTXPhases

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Odyssey Therapeutics reported positive clinical proof-of-concept data for its oral RIPK2 scaffolding inhibitor, OD-001, in a Phase 2a trial for ulcerative colitis. The company has a strong financial position with $464 million expected to support operations through 2028. Odyssey plans to advance OD-001 into late-stage development and initiate additional trials in the near future.

Read more →
Competitive Position
How ODTX ranks across every disease it competes in
Competitive Position is a premium feature
See how ODTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial